Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced/ Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00113516
What this trial is testing

SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 84
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Testing effectiveness (Phase 2)Ended earlyNCT04069936
What this trial is testing

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung CancerLung CancerLung Cancer Metastatic+5 more
WindMIL Therapeutics 19
Testing effectiveness (Phase 2)UnknownNCT05132777
What this trial is testing

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations
Shanghai JMT-Bio Inc. 155
Testing effectiveness (Phase 2)Looking for participantsNCT06929936
What this trial is testing

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung CancerMyelosuppression
The First Affiliated Hospital of Xiamen University 33
Not applicableStudy completedNCT03133234
What this trial is testing

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Who this might be right for
T790M Positive NSCLC Patients
AstraZeneca 47
Large-scale testing (Phase 3)Active Not RecruitingNCT05261399
What this trial is testing

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Who this might be right for
CarcinomaNon-Small-Cell Lung
AstraZeneca 341
Testing effectiveness (Phase 2)Study completedNCT01260181
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07739966
What this trial is testing

DS-3939a in Participants With Solid Tumors

Who this might be right for
Solid TumorLocally Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung Cancer
Daiichi Sankyo 400
Testing effectiveness (Phase 2)WithdrawnNCT05705466
What this trial is testing

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Kartos Therapeutics, Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07630077
What this trial is testing

Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities

Who this might be right for
Non Small Cell Lung Cancer
Sun Yat-sen University 30
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Early research (Phase 1)Study completedNCT03071757
What this trial is testing

The Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 139
Early research (Phase 1)Study completedNCT05631678
What this trial is testing

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 48
Not applicableApproved For MarketingNCT01931306
What this trial is testing

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Early research (Phase 1)Ended earlyNCT02122146
What this trial is testing

PF-06664178 In Patients With Advanced Solid Tumors

Who this might be right for
Neoplasms
Pfizer 31
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Early research (Phase 1)Study completedNCT01219348
What this trial is testing

IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.

Who this might be right for
NSCLCLung Cancer
Inge Marie Svane 14
Not applicableStudy completedNCT05796726
What this trial is testing

Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring METex14 Mutations
Novartis Pharmaceuticals 260
Large-scale testing (Phase 3)Looking for participantsNCT07668752
What this trial is testing

Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

Who this might be right for
KRAS G12D MutationNSCLC (Non-small Cell Lung Cancer)
Genfleet Therapeutics (Shanghai) Inc. 300
Next Page